Rifampicin/isoniazid/pyrazinamide

Rifampicin/isoniazid/pyrazinamide
Combination of
Rifampicin Rifamycin antibiotic
Isoniazid First-line anti-tuberculosis medication
Pyrazinamide Anti-tuberculosis medication
Clinical data
Trade names Rifater, Trifazid
AHFS/Drugs.com FDA Professional Drug Information
Pregnancy
category
  • C
Routes of
administration		 Oral
ATC code J04AM05 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
PubChem (CID) 6474062
  (verify)

Rifampicin/isoniazid/pyrazinamide (trade name Rifater) is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide. It is used in initial treatment of tuberculosis, typically for the first two months.[1][2]

Rifater is contraindicated in children with a body weight of under 40 kg.[2]

The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.

See also

References

  1. ↑ Drugs.com: Rifater
  2. 1 2 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.


This article is issued from Wikipedia - version of the 5/12/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.